BRight DCB First-in-Human Study

NACompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 4, 2021

Primary Completion Date

September 20, 2023

Study Completion Date

February 2, 2024

Conditions
Peripheral Artery Disease
Interventions
DEVICE

BRight DCB

The BRight Drug-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon catheter (BRight DCB) is intended for dilatation of de novo lesions in native superficial femoral or popliteal arteries with a simultaneous release of drug to the vessel wall as a secondary action to reduce occurrence of a restenosis of the treated vessel segment.

Trial Locations (7)

2031

Prince of Wales Hospital, Randwick

8036

Medical University Graz, Graz

59759

Klinikum Hochsauerland, Arnsberg

Unknown

Fiona Stanley Hospital, Perth

Royal Perth Hospital, Perth

Royal North Shore Hospital, Sydney

Auckland City Hospital, Auckland

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Biotronik AG

INDUSTRY

lead

Biotronik CRC Inc.

INDUSTRY

NCT04525794 - BRight DCB First-in-Human Study | Biotech Hunter | Biotech Hunter